Metastatic

Triple Negative ER-,-PR-, HER2-

1st-2nd Line
- PDL-1 Positive
  - BRS0129
    - Phase Ib/II Multiple Immunotherapy-Based Treatment Combinations in Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
      - PI: Telli
      - Hoffmann-La Roche Ltd
  - BRS0126
    - Phase II Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
      - PI: Telli
      - Stanford

1st-4th Line
- PALB2 Mutation
  - BRS0109
    - Phase 1b ATR Inhibitor BAY 1895344 in Combination with Pembrolizumab in Advanced Solid Tumors
      - PI: Telli
      - Sponsor: Bayer Healthcare

Atleast one prior line
- FRA Positive tumors
  - VAR0211
    - Phase III MORAb-202 FolateReceptor Alpha-Targeting Antibody-Drug Conjugate in Selected Tumor Types
      - PI: Berek
      - Stanford

KEY

- Optional Path
- Extension Study
- Immunotherapy
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Enrollment on Hold